329 related articles for article (PubMed ID: 29374852)
1. Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.
Hamy AS; Lam GT; Laas E; Darrigues L; Balezeau T; Guerin J; Livartowski A; Sadacca B; Pierga JY; Vincent-Salomon A; Coussy F; Becette V; Bonsang-Kitzis H; Rouzier R; Feron JG; Benchimol G; Laé M; Reyal F
Breast Cancer Res Treat; 2018 Jun; 169(2):295-304. PubMed ID: 29374852
[TBL] [Abstract][Full Text] [Related]
2. Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy.
Liu YL; Saraf A; Lee SM; Zhong X; Hibshoosh H; Kalinsky K; Connolly EP
Breast Cancer Res Treat; 2016 Jun; 157(3):555-64. PubMed ID: 27225388
[TBL] [Abstract][Full Text] [Related]
3. Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy.
Ryu YJ; Kang SJ; Cho JS; Yoon JH; Park MH
Medicine (Baltimore); 2018 Jul; 97(30):e11647. PubMed ID: 30045313
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
Hamy AS; Darrigues L; Laas E; De Croze D; Topciu L; Lam GT; Evrevin C; Rozette S; Laot L; Lerebours F; Pierga JY; Osdoit M; Faron M; Feron JG; Laé M; Reyal F
PLoS One; 2020; 15(6):e0234191. PubMed ID: 32579551
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
Orsaria P; Grasso A; Ippolito E; Pantano F; Sammarra M; Altomare C; Cagli B; Costa F; Perrone G; Soponaru G; Caggiati L; Vanni G; Buonomo OC; Altomare V
Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
[TBL] [Abstract][Full Text] [Related]
6. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Resende U; Cabello C; Ramalho SOB; Zeferino LC
BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
8. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
Choi M; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
Breast Cancer Res Treat; 2016 Dec; 160(3):475-489. PubMed ID: 27730423
[TBL] [Abstract][Full Text] [Related]
9. Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore.
Laas E; Labrosse J; Hamy AS; Benchimol G; de Croze D; Feron JG; Coussy F; Balezeau T; Guerin J; Lae M; Pierga JY; Reyal F
Br J Cancer; 2021 Apr; 124(8):1421-1427. PubMed ID: 33558711
[TBL] [Abstract][Full Text] [Related]
10. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
11. Predictors of lymphovascular invasion in estrogen receptor positive/Her-2 negative breast cancer patients treated with neoadjuvant chemotherapy.
Çavdar E; İriağaç Y
Turk J Med Sci; 2022 Aug; 52(4):1111-1117. PubMed ID: 36326379
[TBL] [Abstract][Full Text] [Related]
12. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.
Lotan Y; Gupta A; Shariat SF; Palapattu GS; Vazina A; Karakiewicz PI; Bastian PJ; Rogers CG; Amiel G; Perotte P; Schoenberg MP; Lerner SP; Sagalowsky AI
J Clin Oncol; 2005 Sep; 23(27):6533-9. PubMed ID: 16116151
[TBL] [Abstract][Full Text] [Related]
13. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
14. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
15. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.
Truong PT; Yong CM; Abnousi F; Lee J; Kader HA; Hayashi A; Olivotto IA
J Am Coll Surg; 2005 Jun; 200(6):912-21. PubMed ID: 15922205
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.
Kantor O; Laws A; Pastorello RG; King C; Wong S; Dey T; Schnitt S; King TA; Mittendorf EA
Ann Surg Oncol; 2021 Nov; 28(12):7347-7355. PubMed ID: 33956276
[TBL] [Abstract][Full Text] [Related]
17. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
18. The role of lymph node metastasis in the systemic dissemination of breast cancer.
Nathanson SD; Kwon D; Kapke A; Alford SH; Chitale D
Ann Surg Oncol; 2009 Dec; 16(12):3396-405. PubMed ID: 19657697
[TBL] [Abstract][Full Text] [Related]
19. Lymphovascular Invasion Increases the Risk of Nodal and Distant Recurrence in Node-Negative Stage I-IIA Non-Small-Cell Lung Cancer.
Sung SY; Kwak YK; Lee SW; Jo IY; Park JK; Kim KS; Lee KY; Kim YS
Oncology; 2018; 95(3):156-162. PubMed ID: 29847825
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]